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Summations 
• Systematic reviews of observational studies showed a possible increased risk of 
life-threatening medical events associated with exposure to antipsychotic 
drugs, however the certainty of the risk estimates has never been 
quantitatively assessed; 
• An umbrella review of the data on the association between antipsychotics and 
the risk of hip fracture, venous thromboembolism, stroke, myocardial 
infarction, pneumonia, and sudden cardiac death was conducted applying 
AMSTAR-2, GRADE and quantitative umbrella review criteria; 
• We graded the association between antipsychotic exposure and pneumonia as 
“convincing”, followed by the association on hip fracture and venous 
thromboembolism. The data on stroke, sudden cardiac death, and myocardial 
infarction was the least reliable.  
 
Limitations 
• Considering the observational nature of the primary studies, confounding by 
indication may have inflated the risk estimates; 
• We found significant heterogeneity in terms of populations included in the 
primary studies; 
• We were unable to re-analyse the data by antipsychotic class or by individual 
drug, as this information was seldom reported. 
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Abstract 
Objective:To quantify the risk of hip fracture, thromboembolism, stroke, myocardial 
infarction,pneumonia, and sudden cardiac death associated with exposure to 
antipsychotics. 
Methods:Systematic searches were conducted in Medline, Embase, PsychINFO from 
inception until 30/07/2018 for systematic reviews of observational studies. AMSTAR-2 
was used for quality assessment of systematic reviews, while the strength of 
associations was measured using GRADE and quantitative umbrella review 
criteria(URC). 
Results:Sixty-eight observational studies from six systematic reviews were included. 
The association between antipsychotic exposure and pneumonia was the strongest 
(URC=class I; GRADE=low quality; odds ratio [OR]=1.84, 95% confidence interval 
[CI]=1.62-2.09; participants=28,726; age=76.2±12.3years), followed by the association 
with hip fracture (URC=class II; GRADE=low quality; OR=1.57,95%CI=1.42-1.74; 
participants=5,288,118; age=55.4±12.5years), and thromboembolism (URC=class II; 
GRADE=very low quality; OR=1.55,95%CI=1.31-1.83; participants=31,417,175; 
age=55.5±3.2years). The association was weak for stroke (URC=class III; GRADE=very 
low quality; OR=1.45,95%CI=1.24-1.70; participants=65,700; age=68.7±13.8years), 
sudden cardiac death (URC=class III; GRADE=very low quality; OR=2.24,95%CI=1.45-
3.46; participants=77,488; age=52.2±6.2years), and myocardial infarction (URC=class 
III; GRADE=very low quality; OR=2.21,95%CI=1.41-3.46; participants=399,868; 
age=74.1±9.3years). 
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Conclusion:The most robust results were found for the risk of pneumonia, followed by 
the risk of hip fracture and thromboembolism. For stroke, sudden cardiac death, and 
myocardial infarction the strength of association was weak. The observational nature 
of the primary studies may represent a source of bias.  
 
Abstract word count: 200 words. 
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INTRODUCTION 
Antipsychotics (APs) are prescribed in a wide range of health care settings, including 
psychiatric care, primary care, and other medical settings. In the United Kingdom, in 
2010, olanzapine, quetiapine and, risperidone accounted for 24%, 23% and 17% of all 
prescriptions of psychotropic drugs, respectively (1). APs are primarily indicated for the 
treatment of schizophrenia and mood disorder; however, APs are also frequently used 
off-label for the pharmacological treatment of a wide range of other psychiatric and 
medical conditions, such as anxiety disorders, insomnia, agitation and dementias (2, 3). 
In clinical practice, the benefits of APs are often limited by side-effects, including 
extrapyramidal, metabolic, cardiovascular, hepatic and hematological drug reactions 
(4). In addition, APs may be associated with an increased risk of life-threatening 
medical events, such as hip fracture, venous thromboembolism, stroke, myocardial 
infarction, pneumonia, and sudden cardiac death, especially in older adults (5). While 
for common side-effects, typically occurring soon after APs are prescribed, randomized 
clinical trials (RCTs) and systematic reviews (SRs) have been able to precisely describe 
and quantify the increased risk, for life-threatening medical events RCTs may not 
provide satisfactory information (6). Therefore, in recent years, several observational 
studies and subsequently SRs have attempted to describe and quantify the association 
between AP exposure and life-threatening medical events. However, the available data 
are rather controversial, fragmented, and difficult to be stratified into a pragmatic risk 
quantification (7), considering each major medical event in comparison to others. 
Furthermore, the quality of meta-analyses, which is another challenging issue as it 
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clearly has an influence on the certainty of the risk estimates, has never been formally 
synthesized.  
Aims of the study 
In this project, we quantified the risk of the following six life-threatening medical 
events associated with AP exposure: hip fracture, venous thromboembolism, stroke, 
myocardial infarction, pneumonia, and sudden cardiac death. Risks were quantified 
together with a formal assessment of the certainty of estimates using two methods: 
the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
approach, and quantitative umbrella review criteria (7). 
 
METHODS 
Study design 
With the increased number of systematic reviews available, a logical and appropriate 
next step has been the conduct of reviews of existing systematic reviews, allowing the 
findings of separate reviews to be compared and contrasted, thereby providing 
decision makers in healthcare with the evidence they need (11). For this reason we 
performed an umbrella review. The principle reason for the conduct of an umbrella 
review is to summarize the evidence from multiple research syntheses. Basically, 
umbrella reviews are reviews of previously published systematic reviews and meta-
analyses, and consist in the repetition of the meta-analyses following a uniform 
approach for all factors to allow their comparison (12). Conduct of an umbrella review 
offers the possibility of addressing a vast array of issues related to a topic of interest. 
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The conduction of an umbrella review is also ideal to provide a clear picture of broad 
healthcare areas, to highlight whether the evidence base on a topic is consistent or 
contradictory, and to explore potential sources of heterogeneity  for the findings (11, 
13). Umbrella reviews are considered amongst the highest level of evidence (14) and 
are particularly useful to inform policy and clinical decisions (15). A review protocol 
was registered in the International Prospective Register of Systematic Reviews 
(PROSPERO), Registration Number: CRD42018083965. 
 
Literature search 
Two researchers (DP and GO) independently searched Medline, Embase, PsychINFO, 
CINAHL, and Epistemonikos from database inception until 30th July 2018 for SRs with 
quantitative synthesis (meta-analyses) of observational studies investigating the 
association between AP exposure and risk of hip fracture, venous thromboembolism, 
stroke, myocardial infarction, pneumonia and sudden cardiac death. The following 
search algorithm was used: “(antipsychotic) AND (stroke OR sudden cardiac death OR 
venous thromboembolism OR myocardial infarction OR hip fracture OR pneumonia) 
AND (meta-analysis OR systematic review)”. A predefined search strategy was used 
(Supporting information: Table S1). No date or language restrictions, or restrictions on 
the patient population, were applied. Electronic database searches were 
supplemented by a manual search of reference lists from relevant studies. The titles, 
abstracts, and full texts of the resulting articles were examined in detail for eligibility, 
and in case of disagreements, a third author (CB) adjudicated the decision. We 
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documented included and excluded studies following the Preferred Reporting Items 
for Systematic Reviews and Meta-analyses reporting standards (PRISMA) (16). 
Eligibility criteria  
Reviews were considered eligible if the authors had performed a systematic search to 
identify pertinent studies and performed a meta-analysis. We considered SRs of 
observational studies (both case-control and prospective/retrospective cohort studies) 
that examined the association between AP exposure and the risk of developing one of 
the six medical events described above. We excluded SRs that did not present study-
level data, such as for example relative risks (RR) or odds ratios (OR) with 95% 
confidence intervals (CI). When more than one SR on the same research question was 
available, the SR with the largest number of component studies that provided study-
level effect sizes (ES) was considered for inclusion (17, 18). 
Data extraction 
From each included SR, two investigators (DP and GO) independently extracted 
information on first author, year of publication, outcomes, number of included studies, 
and reported summary meta-analytic estimates. All primary observational studies 
included in each SR were retrieved and carefully inspected by two members (DP, GO) 
of the research team. The following information was extracted: year of publication, 
outcome, criteria used to define the occurrence of the medical event under scrutiny, 
mean age, sex, number of events of interest (serious adverse event), number of AP 
exposed and non-exposed subjects, study-specific risk estimates adjusted to the 
largest number of potential confounders (RR, OR, hazard ratio [HR], or standardised 
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incidence ratio [SIR]), and the corresponding 95% CI, studied population, study design 
(case-control or cohort).  
We gave priority to data informing on “current use” of “any antipsychotic drug” (drugs 
belonging to the ATC/DDD Index N05A) (19) at the index date. There was no restriction 
regarding dosage or route of administration. When the original SR presented study 
results separately by sex or drug class (e.g., first- and second-generation APs), we 
combined the summary effects using random effects methods, and then the overall 
meta-analysis was performed. 
Reporting quality of included meta-analyses 
The quality of included SRs was independently assessed by two reviewers (GO, CG) 
using AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews), a 16-point 
assessment tool of the methodological quality of SRs. AMSTAR2 has good inter-rater 
agreement, test-retest reliability, and content validity (20). It assesses reviews on the 
following categories: (1) formulation of the research question; (2) a priori design 
provided; (3) explanation for the chosen study design of the included studies; (4) 
comprehensive literature search; (5) study selection; (6) data extraction; (7) presence 
of a list of excluded studies, along with reason for exclusion; (8) comprehensive 
description of the main features of the included studies; (9) risk of bias assessment; 
(10) information about the sources of funding for the studies included in the review; 
(11) methods for statistical combination of results; (12) assessment of the potential 
impact of risk of bias of individual studies on the meta-analysis result; (13) discussion / 
interpretation of the potential impact of risk of bias of individual studies on the meta-
analysis result; (14) discussion of the heterogeneity observed in the study results; (15) 
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likelihood of publication bias; (16) declaration of study authors’ conflict of interest. Of 
these 16 domains, seven can particularly affect the validity of the review and its 
conclusion and are considered “critical domains” (domains 2 – 4 – 7 – 9 – 11 – 13 – 15). 
Each item allows for the following response options: yes, partial yes, or no. AMSTAR 2 
is not intended to be scored. AMSTAR-2 proposes a scheme for interpreting 
weaknesses detected in critical and non-critical items: “high quality” studies show no 
or one non-critical weakness; “moderate” quality studies show more than one non-
critical weakness but no critical flaws; “low” quality studies show one critical flaw with 
or without non-critical weaknesses; “critically low” quality studies show more than one 
critical flaw with or without non-critical weaknesses (Supporting information: Box S1) 
(20). 
Statistical analysis  
For each medical event of interest, we re-estimated the summary ES and its 95% CI 
using random-effects models because we were expecting high heterogeneity (21). We 
also estimated the 95% prediction interval (PI) for the summary random-effects 
estimates. PIs further account for heterogeneity between studies and specify the 
uncertainty for the effect that would be expected in a new study examining that same 
research question (22). Heterogeneity was evaluated with Cochran’s Q statistic 
(statistically significant for p-value < 0.10) and quantified with the I2 metric (23). I2 
ranges between 0% and 100%, and it is considered low, moderate, large and very large 
for values <25%, 25–49%, 50–74% and >75%, respectively. Egger‘s test was used to 
evaluate potential publication and small-study effects biases (24, 25). In particular, a p-
value ≤ 0.10 in the regression asymmetry test with a more conservative effect in the 
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largest study was considered evidence for small-study effects bias. We further 
evaluated the excess significance, which is a test that examines whether the observed 
number of studies (O) with statistically significant results (positive studies, p<0.05) in 
each meta-analysis is larger than their expected number (E) (26). For each meta-
analysis, E is calculated as the sum of the statistical power estimates for each study in 
the meta-analysis. The power of each study was calculated by an algorithm using a 
non-central t distribution (27). The estimated power depends on the plausible ES. As 
the true ES for any meta-analysis is unknown, we assumed that the most plausible 
effect is given by the largest study. Excess significance for each meta-analysis was 
claimed at p-value ≤ 0.10 level (26). 
Based on these calculations, we applied quantitative umbrella review criteria (7) to 
classify the strength of each association as “convincing”, “highly suggestive”, 
“suggestive”, or “weak” (18, 28-31) (Supporting information: Box S2). Specifically, 
meta-analyses were free from biases (Class I) if they met the following criteria: p-value 
< 10-6 based on random effects meta-analysis; >1000 cases; low or moderate between-
study heterogeneity (I2 < 50%); 95% PI that excluded the null value; no evidence of 
small-study effects and excess significance. Highly suggestive association (Class II) 
criteria required >1000 cases, highly significant summary associations (p-value < 10-6 
by random-effects) and 95% PI not including the null value. Suggestive evidence (Class 
III) criteria required only >1000 cases and p-value ≤ 0.001 by random-effects. Weak 
association (Class IV) criteria required only p-value ≤ 0.05. Associations were 
considered non-significant if p  0.05. The statistical analysis and the power 
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calculations were performed using STATA version 12.0 (STATA Corp, College Station, 
TX, USA). P values were all two-tailed. 
In addition to these umbrella review criteria, the overall certainty in the estimates was 
qualitatively assessed by two reviewers (GO, CG) - with one author (CB) adjudicating 
the decision in case of discrepancies - using the GRADE method (32). GRADE allows to 
rate the certainty of estimate for each outcome and supplies a tabular overview of 
findings easily understandable for patients, policy makers, research planners, guideline 
developers, and other interested stakeholders (33). Summary of Findings tables were 
developed using the GRADEProGDT app. According to the GRADE method, the 
following factors were considered for each outcome of interest: study design, risk of 
bias, consistency, precision, directness, presence of large effect, dose–response 
gradient, and publication bias assessed using visual inspection of funnel plots and 
Egger’s regression test (25). We strictly followed the GRADE method for all ratings 
except for consistency, as for consistency we relied on visual inspection of the forest 
plots only, and we did not use the I2 statistics. This choice was made because meta-
analyses of observational studies include extremely large sample sizes and therefore 
estimates are very precise (narrow CIs) leading to artificially high I2 values (34). Based 
on GRADE assessments, the certainty of estimates was categorized into high, 
moderate, low or very low (35) (Supporting information: Box S3).  
 
Sensitivity analysis and meta-regression 
Sensitivity analyses were performed to assess whether the strength of associations 
varied when only the following studies were retained in the analysis: studies that 
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adjusted for at least 4 covariates; studies with a cohort design. We chose to set 4 
covariates as a threshold because we considered as less credible not only unadjusted 
studies but also studies with scarce adjustment (typically age, sex, body mass index). 
Unrestricted maximum likelihood random effects meta-regressions were used to 
investigate whether there was a relationship between age/sex and risk of each of the 
six considered adverse outcomes. Meta-regressions were performed with 
Comprehensive Meta-Analysis version 2. 
 
RESULTS 
Description of studies included in the meta-analyses 
The systematic search yielded 1584 records. After duplicate removal and title and 
abstract screening, 114 full-text articles were retrieved. Of these, six SRs (36-41), 
including 68 primary studies, met the umbrella review inclusion criteria (Figure 1; 
Supporting information: Table S2). Included SRs assessed whether exposure to APs 
increased the occurrence of hip fracture, venous thromboembolism, stroke, 
myocardial infarction, pneumonia, and sudden cardiac death. Table 1 summarises the 
main review and individual study characteristics. There were between 6 and 24 study 
estimates combined per meta-analysis. All included meta-analyses included >1000 
cases, ranging from 4,906 to 159,283. Of the 68 primary studies, 26 (38%) were cohort 
studies and 42 (62%) adopted a case-control design; 64 studies (94%) provided 
adjusted risk estimates, and 23 (34%) studies adjusted for <4 covariates, usually age 
and sex. Study participants were of either sex, with miscellaneous conditions (69.1%) 
or with dementia (14.7%) or psychiatric conditions (16.2%). Altogether, 58.2 ± 3.6% 
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were female and the mean age of the meta-analysed samples was 55.7 ± 6 years 
(miscellaneous conditions = 68.3 ± 8.4; psychiatric conditions = 49 ± 5.3; dementia = 
78,5 ± 12.4). The mean age of patients in the studies assessing the risk of AP use for 
hip fracture was 55.4 ± 12.5, for venous thromboembolism 55.5 ± 3.2, stroke 68.7 ± 
13.8, myocardial infarction 74.1 ± 9.3, pneumonia 76.2 ± 13.1, and sudden cardiac 
death 52.2 ± 6.2. 
Quality assessment of the included systematic reviews 
Of the six reviews, one was of high quality according to the AMSTAR-2 scoring system 
(36), one was of moderate quality (41), three received a low quality rating (37, 38, 40), 
and one was of critically low quality (39) (Table 2). AMSTAR-2 detected that in three of 
six reviews a study protocol was not available, and study selection criteria were 
unclear. In addition, a list of excluded studies was not provided in four reviews, and 
the source of funding for the studies included in the reviews was never reported. 
Summary effect size 
All six meta-analyses showed significant summary random effects estimates, implying 
that AP use increased the risk of all life-threatening medical events (Figure 2). 
However, when using p ≤ 10-6 as a threshold for significance, the meta-analyses on risk 
of myocardial infarction, sudden cardiac death, and stroke did not produce significant 
summary results (Table 3). 
The effect of the largest primary study included in the meta-analysis of hip fracture, 
venous thromboembolism, stroke, myocardial infarction, pneumonia, and sudden 
cardiac death was significant at p ≤ 0.05, suggesting increased risk (Table 3). For 
myocardial infarction, however, the effect of the largest primary study failed to reach 
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statistical significance. In addition, the effects of the largest studies were more 
conservative than the summary effects of the meta-analysis in four of the six meta-
analyses, indicating that the pooled summary measures were influenced by small 
studies. When we calculated 95% prediction intervals, in only two meta-analyses the 
null value was excluded (for pneumonia and hip fracture).  
Heterogeneity between studies 
There was high heterogeneity (I2 > 75%) in five meta-analyses and low heterogeneity 
(I2 < 50%) in the meta-analysis investigating the association between AP exposure and 
risk of pneumonia (Table 3). 
Small-study effects 
Small-study effects were found only in the meta-analysis on AP exposure and risk of 
venous thromboembolism, suggesting that studies not highlighting an association (i.e. 
the “negative studies”) might exist and might have not been included in the analysis. 
Excess significance 
No meta-analysis provided evidence of excess significance bias using the largest study 
estimate as the plausible ES (p < 0.10).  
Umbrella review criteria 
According to the umbrella review criteria, one association (between APs and 
pneumonia) was “convincing” (class I); two associations (between APs and hip fracture 
and venous thromboembolism) were “highly suggestive” (class II); three associations 
(between APs and: stroke, myocardial infarction, sudden cardiac death) were 
“suggestive” (class III) (Table 3; Supporting information: Content S1). We found no 
non-significant associations. 
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Certainty of evidence according to the GRADE approach 
Table 4 shows the certainty in estimate for each medical outcome, assessed using 
GRADE. For the outcomes stroke, venous thromboembolism, sudden cardiac death, 
and myocardial infarction, the certainty was rated as “very low”, mainly because of 
inconsistency, imprecision and risk of publication bias. For hip fracture and 
pneumonia, the certainty was rated as “low”, based on the GRADE baseline 
assumption of low certainty for observational studies.  
Overall ranking 
Figure 2 presents a ranking of associations based on AMSTAR-2, umbrella review 
criteria, and GRADE. The association between AP exposure and pneumonia was the 
most reliable, followed by hip fracture and venous thromboembolism. The association 
on stroke, sudden cardiac death, and myocardial infarction was weak. 
Sensitivity and meta-regression analyses  
Limiting the analysis to studies that adjusted for at least 4 confounders, the association 
between AP exposure and pneumonia, hip fracture, stroke and sudden cardiac death 
remained “convincing”, highly suggestive and suggestive, respectively. However, the 
association with venous thromboembolism was downgraded from highly suggestive to 
suggestive, and the association with myocardial infarction was downgraded from 
suggestive to weak (Supporting information: Content S2). 
Limiting the analysis to cohort studies was not possible for pneumonia, as only one 
study employed a cohort design. For hip fracture, the strength of association did not 
change, while the other associations were downgraded by one level (stroke, 
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myocardial infarction) and by two levels (venous thromboembolism, sudden cardiac 
death) (Supporting information: Content S3). 
Meta-regression analyses did not detect any relationship between age and risk of hip 
fracture (p = 0.54) and sudden cardiac death (p = 0.17). By contrast, for venous 
thromboembolism (p < 0.01), stroke (p = 0.04), pneumonia (p = 0.04) and myocardial 
infarction (p = 0.04) a negative association with age was observed (Supporting 
information: Content S4). Meta-regression analyses with sex as the moderator variable 
did not detect any significant relationship with any of the six medical conditions 
(Supporting information: Content S5). 
 
DISCUSSION 
To our knowledge, this is the first umbrella review summarising the data on the 
association between AP exposure and risk of life-threatening medical events across a 
broad range of conditions encompassing schizophrenia, dementia, neurological and 
other medical conditions (Table 1). Considering the quality of existing SRs, and the 
certainty of estimates measured qualitatively with GRADE and quantitatively with 
several umbrella review criteria, the most robust results were found for the risk of 
pneumonia, followed by the risk of hip fracture and thromboembolism. For stroke, 
sudden cardiac death, and myocardial infarction the strength of association was weak. 
Sensitivity analyses provided results in line with these findings. In terms of magnitude 
of risk, the relative risk increased from 45% for stroke to 84% for pneumonia and was 
more than doubled for myocardial infarction and sudden cardiac death. In absolute 
terms, these risks correspond to a number needed to harm (NNH) ranging from 87 for 
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pneumonia to more than 1,800 for sudden cardiac death (Supporting information: 
Table S3).   
For myocardial infarction, pneumonia, venous thromboembolism and stroke, the 
increased risk associated with APs was higher in studies carried of younger populations 
versus studies in older populations. This finding appears to be counterintuitive, as the 
incidence of these outcomes increases with age in the general population, probably 
because most risk factors, including comorbidities, are age-related (42-45). However, 
there was a significant difference in the age across study populations, in that studies 
conducted in patients with a psychiatric diagnosis (schizophrenia, bipolar disorder), 
who were likely exposed to APs to a relevant higher degree, had much lower mean 
ages than studies conducted in other patient populations, who were likely exposed to 
APs only in rare occasions. Moreover, it is possible that in late life, when the absolute 
baseline risk for the medical life threatening outcomes under study is high, AP 
exposure adds little relative risk. As the included studies enrolled participants suffering 
from miscellaneous clinical conditions, subgroup analyses by diagnosis was not 
possible. However, the review by Papola and colleagues (36) and Nosè and colleagues 
(40) found no significant differences between patients with psychiatric diagnoses 
(schizophrenia and bipolar disorder) and patients with cognitive impairment or 
dementia on the risk of hip fracture and pneumonia, respectively. By contrast, Huang 
and colleagues (39) reported a higher risk of myocardial infarction in patients with 
schizophrenia (OR=2.25, CI 1.98 to 2.55, I2=6%), as compared with those with other 
diagnoses. Moreover, results from Hsu (38) and colleagues suggested that elderly patients 
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without dementia might have a higher risk of cardiovascular events than patients with 
dementia (OR=1.49, CI=1.25–1.77, I2=89% VS OR=1.17, CI=1.08–1.26, I2=0%, respectively). 
The different strength of association between AP use and medical events have 
implications for clinical practice. As in clinical practice APs are used in a miscellaneous 
group of diagnostic entities, which go well beyond the presence of approved 
indications, such as mania, delusions and hallucinations or augmentation of 
antidepressants in patients with suboptimal antidepressant response (2, 3), deciding 
whether an AP should be prescribed should consider these life-threatening medical 
conditions, which, in turn, may negatively interact with pre-existing physical health 
conditions. This risk-benefit evaluation may be extremely relevant, for example, for 
older adults with behavioural and psychological symptoms of dementia, where 
epidemiological data have documented extensive use of APs, despite evidence of only 
modest beneficial effects (46). There is also evidence of increasing use of second-
generation APs for insomnia and related sleep disorders (47), and high AP prescribing 
has additionally been documented in nursing home residents (48). In all these 
circumstances, it would be important to consider if the expected benefit of treatment 
clearly outweighs the potential drawbacks, especially if treatment is not occasional. 
Among potential drawbacks, not only the most frequent and well-known AP adverse 
effects, but also the less frequent, but potentially life-threatening medical conditions 
need to be considered, especially the risk of pneumonia, where the evidence is most 
robust. Particular attention needs to be given to the fact that the frequency of these 
medical conditions is likely to increase in the presence of pre-existing risk factors. For 
example, obesity, smoking, increasing age, physical inactivity and a sedentary life-style 
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are all risk factors for thromboembolism (49). Therefore, the different strengths of 
associations identified in this umbrella review should be used in conjunction with 
knowledge about risk factors inherent in the patient and associated with co-
treatments, among other considerations, to optimize and personalize the 
individualized choice, use and monitoring of APs in clinical practice. 
These different levels of evidence may also have implications for guideline 
development, in particular for conditions where the use of APs is not backed by 
substantial evidence of efficacy, such as for example anxiety disorders, insomnia and 
sleep problems, dementia-related behavioural disinhibition, neurological and medical 
conditions. In these conditions, tolerability clearly becomes a key argument, and 
guidelines may therefore consider, in addition to randomised evidence, the differential 
risk of these rare, but life-threatening medical conditions. By contrast, as in individuals 
with several severe mental disorders the use of APs is backed by substantial evidence 
of efficacy, and the prevalence of such serious adverse events is rare, with high NNH as 
opposed to low number needed to treat (NNT) (50), different recommendations may 
be drawn based on these results in these circumstances.  
A number of limitations associated with this study need to be considered. A general 
cautionary note is that, although all the statistical tests that we applied are standard in 
this field (23-27), their use for the URC classification is relatively new, and employed so 
far to classify strength of associations in some areas only. A second general cautionary 
note is the observational nature of the primary studies which does not allow to 
establish a causal association. Very few among the included studies fully matched the 
two compared populations for underlying risk factors, raising concerns about the 
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possibility of confounding by indication. The possibility that receiving AP drugs 
reflected more vulnerability to experiencing the outcomes of interest cannot be ruled 
out, and therefore the extent to which adjustment for baseline factors accounted for 
this potential imbalance remains uncertain. It should be noted, however, that this risk 
is taken into consideration by GRADE, which suggests to rate the certainty of estimates 
from observational studies as “low quality” instead of “high quality”, to fully 
acknowledge confounding by indication. Another concern is heterogeneity in terms of 
populations included in the primary studies. Clinically, it would have been relevant to 
stratify the risk of medical events by variables that may act as risk factors for the 
occurrence of these medical outcomes, including medical and psychiatric conditions. 
Unfortunately, the diagnostic groups were too heterogeneous and sparsely 
characterized to allow for a moderator analysis based on the primary diagnosis. 
Indeed, despite attempts to describe the main characteristics of the included 
populations, in most studies very heterogeneous populations were enrolled, making it 
very difficult to clearly define to which specific population the results may apply. As for 
SRs of clinical trial data, future SRs of observational studies should attempt to access 
individual-level patient data, so that the meta-analytic approach can be applied to 
more homogeneous subgroups of participants, for example those meeting some 
diagnostic criteria, or those belonging to a particular age group or setting of care. We 
argue that the culture of data sharing (51, 52), which has progressively received 
increasing attention in the field of clinical trials, will be similarly applied to the field of 
observational studies (53), aiming to make the best use of available data. A second 
limitation is that we were unable to re-analyse the data by AP class or by individual 
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drug, as this information was seldom reported. Again, this would have been extremely 
relevant clinically, especially for those situations where prescribers have already 
decided that an AP should be prescribed, but the decision of which AP should be 
selected may be controversial. In these circumstances, information on differences 
between APs would have been useful to guide clinical practice. In addition to drug class 
or type, other information that would have been important to re-analyse is whether 
the risk of medical events is moderated by AP dose and length of treatment. 
Unfortunately, this was not feasible due to the nature of primary data.  
Nevertheless, despite these limitations inherent in the primary data, to our knowledge, 
this is the first umbrella review that critically appraised the existing data on a topic 
using an approach based on three complementary tools. AMSTAR-2 was used to assess 
the reporting quality of SRs, GRADE allowed to qualitatively rate the certainty of 
estimates by outcome of interest, and quantitative umbrella review criteria were 
employed to quantitatively measure the strength of associations between AP drug 
exposure and the outcomes of interest. Based on these tools, it was possible to 
generate a clinically useful hierarchy for the six considered medical outcomes. We 
reasoned that GRADE and the umbrella review criteria have complementary 
characteristics, and therefore their simultaneous use was intended to provide a more 
complete description of the available data. More specifically, the umbrella review 
criteria are based on quantitative indicators, such as number of included participants, 
significance level of statistical associations, evidence of small-study effects and of 
excess of significance bias, calculation of prediction intervals, presence of 
heterogeneity, and whether the largest primary study provides significant results. 
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Being based on objective criteria, it is possible to categorize the strength of 
associations into different levels, allowing comparisons and informing clinical and 
policy practice. However, the context to which the results may be applied is not taken 
into consideration. By contrast, GRADE, which is only partially based on objective 
measures, takes context aspects into careful consideration. For example, according to 
the GRADE approach, the extent of similarity (in terms of populations, interventions, 
outcome measures, and comparisons) between the available studies and the target 
context of application is a key component of the certainty of estimates. This makes the 
GRADE approach substantially different from the umbrella review criteria, as it 
provides a wider perspective that is based on qualitative judgments that account for 
applicability and context-related aspects.  
In conclusion, the strength of association between antipsychotic use and risk of 
pneumonia was convincing, while the association with hip fracture and 
thromboembolism was highly suggestive, yet with a low quality according to GRADE. 
All other associations were weaker. These conclusions should consider that the 
observational nature of the primary studies cannot prove causality. 
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Table 1. Main characteristics of studies included in the six meta-analyses 
 
 
First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
Individual 
studies 
included in 
the hip 
fracture 
review 
Koponen 2017 HF ICD-10 2971 54617 57588 64 - Alzheimer disease retrospective  HR 1.54 1.39 1.7 
Dennis 2017 HF ICD-10 399 9035 9434 82 - Dementia retrospective  PERR 1.62 1.59 1.65 
Bakken 2016 HF unclear 39938 866484 906422 73 56 Miscellaneous conditions retrospective  SIR 2.1 1.9 2.2 
Leach 2015 HF ICD-10  4418 4418 8828 88 63 Miscellaneous conditions case-crossover OR 1.47 1.21 1.8 
Bohlken 2015 HF ICD-10  Unknown Unknown 106312 81 61 Dementia retrospective  HR 1.2 1.01 1.41 
Fraser 2015 HF ICD-10  12315 183239 195554 81 65 Dementia retrospective  OR 1.67 1.53 1.81 
Wu 2015 HF ICD-9 605 2828 3433 58 45 
Schizophrenia and related 
conditions 
nested case-
control 
OR 1.34 1.07 1.69 
Rigler 2013 HF unclear 79 8183 8262 83 72 
Miscellaneous conditions 
(61% with dementia) 
retrospective  HR 1.76 1.08 2.87 
Soresen 2013 HF ICD-10 15431 3807597 3823028 48 - Schizophrenia case-control RR 1.42 1.21 1.65 
Pouwels 2013 HF unclear 275 9099 9374 74 42 Parkinson disease retrospective  HR 1.24 0.79 1.96 
Baker 2010 HF unclear 617 19487 20104 79 65 Dementia retrospective  HR 3.6 1.3 10 
Howard 2007 HF ICD-9 16341 29889 46230 79 79 Schizophrenia case-control OR 2.6 2.43 2.78 
Kaye 2004 HF unclear 32827 65295 98122 48 55 Miscellaneous conditions 
nested case-
control 
RR 1.4 1.2 1.6 
Jacquim-
Gadda 
1998 HF 
self 
reported 
285 2931 3216 75 - Miscellaneous conditions prospective  OR 1.41 0.46 4.3 
Jensen 1991 HF ICD-9 200 200 400 81 - Miscellaneous conditions case-control OR 1.47 0.73 2.97 
Jalbert 2010 HF ICD-9 764 3582 4346 83 75 Miscellaneous conditions 
nested case-
control 
OR 1.26 1.05 1.52 
Pouwels 2009 HF unclear 6763 26341 33104 79 73 Miscellaneous conditions case-control OR 1.68 1.43 1.99 
Kolanowski 2006 HF ICD-9 90 959 1049 75 - Dementia retrospective  OR 264 1.04 6.72 
Hugenholtz 2005 HF ICD-9 22250 22250 44500 77 76 Miscellaneous conditions case-control OR 1.3 1.1 1.5 
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First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
Wang 2001 HF unclear 1222 4888 6110 82 84 Miscellaneous conditions case-control OR 1.61 1.29 2.01 
Guo 1998 HF ICD-9 134 1474 1608 82 - Miscellaneous conditions prospective  RR 0.86 0.4 1.84 
Lichtenstein 1994 HF ICD-9 129 234 363 82 67 Miscellaneous conditions case-control OR 0.79 0.23 2.7 
Cumming 1993 HF unclear 209 207 416 80 75 Miscellaneous conditions case-control OR 1.28 0.64 2.5 
Ray 1987 HF ICD-9 1021 5606 6627 81 77 Miscellaneous conditions case-control OR 2 1.6 2.6 
 
Hip 
fracture 
systematic 
review 
Papola36 2018 HF  159.283 5.128.843 5.394.430 
55,4 
(12.5
) 
52% 
Dementia (6/24 studies) 
Schizophrenia (3/24) 
Parkinson/Parkinsonism 
(1/24) 
Miscellaneous conditions 
(14/24) 
12 case-
control, 
2 prospective, 
9 
retrospective, 
1 case cross-
over 
OR 1.57 1.42 1.74 
Individual 
studies 
included in 
the venous 
thromboe
mbolism 
review 
Allenet 2012 PE ICD-9 76814 28646957 28723771 56 59 Miscellaneous conditions retrospective  OR 1.17 1.13 1.21 
Hamanaka 2004 PE 
Autopsy 
criteria 
28 1097 1125 55 100 Miscellaneous conditions case-control OR 
10.4
9 
3.95 27.85 
Parkin 2003 PE ICD-9 62 243 305 43 32 Miscellaneous conditions case-control OR 13.3 2.3 76.3 
Kleijer 2010 VTE ICD-9 1032 4125 5157 76 67 Miscellaneous conditions case-control OR 0.9 0.73 1.1 
Ray 2002 VTE ICD-9 22514 33033 55547 75 72 Miscellaneous conditions retrospective  OR 1.1 0.95 1.27 
Liperoti 2005 VTE ICD-9 539 131479 132018 80 72 Miscellaneous conditions retrospective  HR 1.25 0.99 1.56 
Parker 2010 VTE unclear 25532 89491 115023 67 56 Miscellaneous conditions 
nested case-
control 
OR 1.32 1.19 1.47 
Hipplsley-Cox 2001 VTE ICD-9 14756 2299945 2314701 47 49 Miscellaneous conditions prospective  HR 1.67 1.41 1.98 
Jonsson 2009 VTE 
ICD-8 and 
ICD-10 
5999 59990 65989 65 55 Miscellaneous conditions 
nested case-
control 
RR 1.87 1.53 2.28 
Ishiguro 2011 VTE 
Autopsy 
criteria 
112 375 487 40 - Miscellaneous conditions case-control OR 2.11 0.68 6.75 
Masopust 2007 VTE unclear 266 274 540 43 51 Miscellaneous conditions case-control OR 2.76 1.01 7.55 
Lacut 2007 VTE unclear 677 677 1354 68 57 Miscellaneous conditions case-control OR 3.7 1.9 7.1 
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First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
Zornberg 2000 VTE ICD-8  42 168 210 44 76 Miscellaneous conditions case-control OR 7.1 2.3 21.9 
Thomassen 2001 VTE 
objective 
tests 
474 474 948 43 - Miscellaneous conditions case-control OR 9.07 0.48 169.05 
Venous 
thromboe
mbolism 
systematic 
review 
Barbui37 2014 VTE  148.847 31.268.328 31.417.175 
55.5 
(3.2) 
58% Miscellaneous conditions 
10 case-
control, 
1 prospective, 
3 retrospective 
OR 1.55 1.31 1.83 
Individual 
studies 
included in 
the stroke 
review 
Liperoti 2005 
Stroke 
/ TIA 
ICD-9 1130 3658 4788 82 71 Dementia case-control OR 1.2 0.95 1.52 
Douglas 2008 Stroke ICD-10 3395 3395 6790 80 - Miscellaneous conditions self-controlled  RR 1.73 1.6 1.87 
Kleijer 2009 Stroke ICD-9 518 2030 2548 76 56 Miscellaneous conditions 
nested case-
control 
OR 1.6 1.29 1.98 
Chan 2010 CVA unclear 107 982 1089 80 66 Dementia retrospective  HR 0.98 0.62 1.54 
Laredo 2011 CVA ICD-9  3149 15613 18762 81 69 Dementia 
nested case-
control 
OR 1.17 1.06 1.29 
Wang 2012 Stroke ICD-9 255 256 511 69 2 Miscellaneous conditions 
case-case time 
control 
OR 1.8 1.7 1.9 
Hsieh 2013 
Stroke 
/ TIA 
ICD-9 386 772 1158 57 50 Schizophrenia 
nested case-
control 
OR 1.94 1.11 3.39 
Liu 2013 Stroke ICD-9 811 1432 2243 78 53 Dementia retrospective  HR 1.17 0.99 1.38 
Mundet-
Tuduri 
2013 Stroke ICD-10 1084 26727 27811 54 53 Miscellaneous conditions cross-sectional OR 1.89 1.35 2.65 
Stroke 
systematic 
review 
Hsu38 2017 Stroke  10.835 54.865 65.700 
68,7 
(13.8
) 
58% 
Dementia (4/9 studies 
studies) 
Schizophrenia (1/9) 
Miscellaneous conditions 
(4/9) 
4 case-control, 
2 
retrospective, 
1 cross-
sectional, 
1 self-
controlled case 
series, 
1 case-case 
time control 
OR 1.45 1.24 1.70 
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First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
Individual 
studies 
included in 
the 
myocardial 
infarction 
review 
Thorogood 1992 
Death 
by MI 
ICD-9 161 309 470 27 100 
Miscellaneous conditions 
(women) 
case-control RR 6.2 2 19.1 
Penttinen 1996 MI ICD-9 83 249 332 - 0 
Miscellaneous conditions 
(men) 
case-control OR 1.5 0.4 6 
Pratt 1996 MI 
self-
reported 
63 1559 1622 40 62 Miscellaneous conditions prospective  OR 2.92 1.23 6.98 
Enger 2004 MI ICD-9 40 11480 11520 39 58 Schizophrenia retrospective  RR 4.81 2.44 9.46 
Nakagawa 2006 MI ICD-10 21377 106885 128262 69 39 Miscellaneous conditions case-control RR 0.99 0.96 1.02 
Lin 2014 MI ICD-9 29903 29903 59806 71 48 
Schizophrenia (10%); 
Mood disorders (36%); 
Dementia (54%). 
case-crossover OR 2.52 2.37 2.68 
Brauer 2015 MI unclear 734 734 1468 70 44 Miscellaneous conditions 
self-controlled 
case series 
RR 2.76 2.02 3.77 
Wu 2015 MI ICD-9 295 296 834 57 40 Schizophrenia case-crossover OR 2.13 1.49 3.06 
Hwang 2014 MI ICD-9 97777 97777 195554 81 - Miscellaneous conditions retrospective  RR 1.13 0.97 1.32 
Myocardial 
infarction 
systematic 
review 
Huang39 2017 MI  150.433 249.192 399.625 
74,1 
(9.2) 
46% 
Schizophrenia (2/9 
studies) 
Miscellaneous population 
(7/9) 
3 case-control, 
1 prospective,  
2 
retrospective, 
2 case cross-
over, 
1 self-
controlled case 
series 
OR 2.21 1.41 3.46 
Individual 
studies 
included in 
the 
pneumonia 
review 
Gau 2010 PN 
Medical 
records 
and 
radiograp
hic 
findings 
194 952 1146 80 64 Miscellaneous conditions case-control OR 2.26 1.23 4.15 
Knol 2008 PN 
Medical 
records 
543 2163 2706 80 64 Miscellaneous conditions 
nested case-
control 
OR 1.9 0.5 7.4 
Kuo 2013 PN ICD 1739 6949 8688 63 37 Schizophrenia case-control RR 1.64 1.4 1.92 
37 
 
 
First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
Pratt 2011 PN ICD 1914 11410 13324 85 - Miscellaneous conditions 
self-controlled 
case series 
IRR 1.64 1.32 2.04 
Trifirò 2010 PN 
Medical 
records 
and 
radiograp
hic 
findings 
258 1689 1947 83 71 Miscellaneous conditions 
nested case-
control 
OR 1.97 1.45 2.69 
Yang 2013 PN ICD  258 657 915 44 39 Bipolar Disorder case-control RR 2.19 1.8 2.65 
Pneumonia 
systematic 
review 
Nosé40 2015 PN  4.906 23.820 28.726 
76,2 
(12.3
) 
49% 
Schizophrenia (1/6 
studies) 
Bipolar disorder (1/6 
studies) 
Miscellaneous conditions 
(4/6) 
5 case-control 
1 self-
controlled case 
series 
OR 1.84 1.62 2.09 
Individual 
studies 
included in 
the sudden 
cardiac 
death 
review 
Jones 2013 
life-
threate
ning VA 
ICD-10 1146 376166 377312 56 58 Psychiatric disorders retrospective  RR 1.16 1.02 1.31 
Ray 2009 
SCD by 
VA 
Deaths 
compatibl
e 
with SCD 
1684 278216 279900 46 67 Miscellaneous conditions retrospective  IRR 1.91 1.65 2.21 
Jolly 2009 
SCD by 
VA 
post-
mortem 
examinati
on 
1010 3030 4040 67 33 Miscellaneous conditions case-control OR 4.29 2.68 6.88 
Van Noord 2011 
SCD by 
VA 
Deaths 
compatibl
e 
with SCD 
1424 14443 15867 70 40 Miscellaneous conditions case-control OR 3.9 2.06 7.37 
Reilly 2002 
SCD by 
VA 
Deaths 
compatibl
e 
with SCD 
69 138 207 66 67 Psychiatric disorders case-control OR 7.6 0.54 108.1 
Kenbubpha 2002 
SCD by 
VA 
Deaths 
compatibl
54 108 162 40 37 Miscellaneous conditions case-control OR 1.58 0.68 3.65 
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First author  Year 
Outco
me 
Outcome 
definition 
N. of 
patients 
with the 
event 
N. of 
patients 
without  
the event 
Total N. of 
participant
s 
Mea
n 
Age 
(SD) 
Fem
ale 
sex 
(%) 
Population†‡ Study design 
Type 
of 
metric 
ES 
Low
er 
95% 
CI 
Upper 
95% CI 
e 
with SCD 
Sudden 
cardiac 
death 
systematic 
review 
Salvo41 2016 
SCD by 
VA 
 5.387 672.101 677.488 
52.2 
(6.2) 
61% 
Psychiatric disorders (2/6 
studies) 
Miscellaneous conditions 
(4/6) 
4 case-control, 
2 retrospective 
OR 2.24 1.45 3.46 
 
Explanations 
ICD = International Classification of Diseases; OR = Odds Ratio; RR = Relative Risk; IRR = International Rate Ratio; PERR = Prior Event Risk Ratio; SIR = Standardized Incidence Ratio; ES = Effect Size; HF= Hip 
Fracture; PE = Pulmonary Embolism; VTE = Venous Thromboembolism; CVA = cerebrovascular accident; MI = Myocardial Infarction; TIA= Transient Ischemic Attack; PN = Pneumonia; SCD = Sudden Cardiac 
Death. 
† “Miscellaneous population”: it is likely that patients considered for these studies suffered from medical/psychiatric condition that justified an antipsychotic prescription, but the original investigation didn’t 
report it or did it in in a way that cannot be used to identify a well-defined population. 
‡ mean age of participants ordered by diagnosis (SD): HIP FRACTURE: dementia: 78,4 (11.5) years; schizophrenia: 48,38 (5.7) years; Parkinson: 74 years; miscellaneous population: 71,5 (9.8) years. VENOUS 
THROMBOEMBOLISM: miscellaneous population: 55,5 (7.2) years. STROKE: dementia: 80,9 (10.3) years; miscellaneous population: 60,4 (10.6) years. MYOCARDIAL INFARCTION: miscellaneous population: 
75,2 (13.1) years; psychiatric population: 40,2 (5.5) years. PNEUMONIA: miscellaneous population: 83,8 (11.7) years; psychiatric population: 61,2 (8.2) years. SUDDEN CARDIAC DEATH: miscellaneous 
population: 47,5 (5.9) years; psychiatric population: 56 (6.2) years. 
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Table 2. AMSTAR-2 appraisal  
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Papola et al., 
201836 
- 
Hip fracture 
Barbui et al., 
201437 
- 
VTE 
Hsu et al., 
201738 
- 
stroke 
Haung et al., 
201739 
- 
MI 
Nosé et al., 
201540 
- 
Pneumonia 
Salvo et al., 
201641 
- 
SCD 
1 
Did the research questions and inclusion criteria 
for the review include the components of PICO? 
 
√ √ √ √ √ √ 
2 
Did the report of the review contain an explicit 
statement that the review methods were 
established prior to the conduct of the review 
and did the report justify any significant 
deviations from the protocol? 
√ √ × × √ partially 
3 
Did the review authors explain their selection of 
the study designs for inclusion in the review? 
√ 
√ 
 
× √ √ √ 
4 
Did the review authors use a comprehensive 
literature search strategy? 
√ 
√ 
 
√ √ √ √ 
5 
Did the review authors perform study selection in 
duplicate? 
√ √ √ √ √ × 
6 
Did the review authors perform data extraction in 
duplicate? √ √ × √ √ × 
7 
Did the review authors provide a list of excluded 
studies and justify the exclusions? √ partially partially × × √ 
8 
Did the review authors describe the included 
studies in adequate detail? 
√ √ partially √ √ √ 
9 
Did the review authors use a satisfactory 
technique for assessing the risk of bias (RoB) in 
individual studies that were included in the 
review? 
√ √ √ √ √ √ 
10 
Did the review authors report on the sources of 
funding for the studies included in the review? × × × × × × 
11 
If meta-analysis was performed did the review 
authors use appropriate methods for statistical 
combination of results? 
√ √ √ √ √ √ 
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Explanation 
“Critical” domains are in bold. 
 
 
 
 
 
 
 
 
12 
If meta-analysis was performed, did the review 
authors assess the potential impact of RoB in 
individual studies on the results of the meta-
analysis or other evidence synthesis? 
√ √ √ × √ √ 
13 
Did the review authors account for RoB in 
individual studies when interpreting/ discussing 
the results of the review? 
√ 
 
√ 
 
√ × √ √ 
14 
Did the review authors provide a satisfactory 
explanation for, and discussion of, any 
heterogeneity observed in the results of the 
review? 
√ √ √ √ √ √ 
15 
If they performed quantitative synthesis did the 
review authors carry out an adequate 
investigation of publication bias (small study 
bias) and discuss its likely impact on the results 
of the review? 
√ × √ √ √ √ 
16 
Did the review authors report any potential 
sources of conflict of interest, including any 
funding they received for conducting the review? 
√ √ × √ √ √ 
Reporting quality of each meta-analysis High low low 
 
Critically low 
 
low moderate 
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Table 3. Strength of association according to umbrella review criteria 
 
  
Features used for classification of associations according to Umbrella Review Criteria 
 
Outcome 
Number of 
cases 
Random-
effects P-
value 
I2 
 
MA 
Predictive 
Intervals 
Random-effects ES 
(95% CI) of the 
largest study 
Egger’s 
test P-
value 
Significant studies 
Strength of 
association 
Observed Expected§ P-value† 
Pneumonia 4.906 7,1 X 10-21 27 1.38 – 2.45 1.64 (1.40 – 1.92) 0.35 4 6 NR I 
Hip Fracture 159.283 1.2 X 10-18 92 1.03 – 2.41 1.62 (1.59 – 1.65) 0.76 10 17.2 NR II 
Venous Thromboembolism 148.847 3.4 X 10-7 87 0.91 – 2.65 1.17 (1.13 – 1.21) 0.05 3 12.2 NR II 
Stroke 10.835 2,9 X 10-6 91 0.86 – 2.45 1.80 (1.70 – 1.90) 0.65 4 7.34 NR III 
Myocardial Infarction 150.433 0.00053 99 0.47 – 10.42 0.99 (0.96 – 1.02) 0.16 1 6.53 NR III 
Sudden Cardiac Death 5.387 0.00029 91 0.56 – 8.95 1.16 (1.02 – 1.31) 0.19 2 5.11 NR III 
 
Explanations 
ES = effect-size; MA = meta-analysis; NR = not relevant. 
§ Observed and expected number of significant studies using effect of largest study (smallest SE) of each meta-analysis as plausible effect size. 
†P value of excess significance test. All statistical tests two sided. 
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Table 4. GRADE appraisal 
 
Certainty assessment  
Relative 
(95% CI) 
Certainty 
Outcome 
№ of 
studies 
Study design Risk of bias Inconsistency 
Indirectnes
s 
Imprecision 
Other 
considerations 
Hip fracture 24 
observational 
studies 
not serious not serious not serious not serious none 
OR 1.57 
(1.42 to 1.74) 
⨁⨁◯◯ 
LOW 
Thromboem
bolism 
14 
observational 
studies 
not serious serious d not serious not serious 
publication bias 
strongly 
suspected 
OR 1.55 
(1.31 to 1.83) 
⨁◯◯◯ 
VERY LOW 
Stroke 9 
observational 
studies 
not serious serious c not serious not serious none 
OR 1.45 
(1.24 to 1.70) 
⨁◯◯◯ 
VERY LOW 
Myocardial 
Infarction 
9 
observational 
studies 
not serious serious a not serious serious b 
publication bias 
strongly 
suspected;  
OR 2.21 
(1.41 to 3.46) 
⨁◯◯◯ 
VERY LOW 
Pneumonia 6 
observational 
studies 
not serious not serious not serious not serious none 
OR 1.84 
(1.62 to 2.09) 
⨁⨁◯◯ 
LOW 
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Certainty assessment  
Relative 
(95% CI) 
Certainty 
Outcome 
№ of 
studies 
Study design Risk of bias Inconsistency 
Indirectnes
s 
Imprecision 
Other 
considerations 
Sudden 
cardiac 
death 
6 
observational 
studies 
not serious not serious not serious serious b none 
OR 2.24 
(1.45 to 3.47) 
⨁◯◯◯ 
VERY LOW 
 
 
CI: Confidence interval; OR: Odds ratio 
Explanations 
a. Visual inspection of forest plot suggested heterogeneity; I-squared = 99%; 
b. Wide confidence interval; 
c. Visual inspection of forest plot suggested heterogeneity; I-squared = 91%; 
d. Visual inspection of forest plot suggested heterogeneity; I-squared = 87%. 
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FIGURE LEGENDS 
 
 
 
 
Figure 1. PRISMA flow-diagram. 
 
 
 
 
 
Figure 2. Ranking of associations on the risk of life-threatening medical events associated with exposure to antipsychotic drugs 
Explanations: 
1 High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: the true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different. Low certainty: The true effect may be substantially different from the estimate of the effect. Very low certainty: the true 
effect is likely to be substantially different from the estimate of effect. 
2 Convincing evidence (Class I): more than 1000 cases + significant summary associations (p<10-6) per random-effects calculations + no evidence of small-study effects + no evidence of 
excess of significance bias + prediction intervals not including the null value + largest study nominally significant (p<0.05) + not large heterogeneity (i.e., I2< 50%). Highly Suggestive 
evidence (Class II): more than 1000 cases + significant summary associations (p<10-6) per random-effects calculation + largest study nominally significant (p<0.05). Suggestive Evidence 
(Class III): more than 1000 cases + significant summary associations (p<10-3) per random-effects calculations. Weak evidence (Class IV): All other associations with p < 0.05. Non-
significant associations: All associations with p >0.05. 
3 High: No or one non-critical weakness: the systematic review provides an accurate and comprehensive summary of the results of the available studies that address the question of 
interest. Moderate: more than one non-critical weakness: the systematic review has more than one weakness but no critical flaws. It may provide an accurate summary of the results 
of the available studies that were included in the review. Low: one critical flaw with or without non-critical weaknesses: the review has a critical flaw and may not provide an accurate 
and comprehensive summary of the available studies that address the question of interest. Critically low: more than one critical flaw with or without non-critical weaknesses: the 
review has more than one critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available studies. 
 
